A new vaccine against coronavirus has been developed. The animal tests of the new vaccine, which was about the size of the fingertip, were successful. Scientists are waiting for the vaccine to be allowed to begin human testing.
To stop the coronavirus pandemic vaccination studies continues. Human testing of vaccines that work in animals started quickly. Tests and reviews are ongoing to get the long-term results of these vaccines.
According to a new report, researchers from the University of Pittsburgh Medical School, one of the prestigious medical faculties of the USA, have developed a new vaccine against coronavirus. The developed vaccine is thought to be sufficient to neutralize the virus in mouse tests. SARS-CoV-2 antibodies managed to produce.
Andrea Gambotto, of the University of Pittsburgh Medical School, who played a role in the development of the coronavirus vaccine, said that they are experienced with SARS in 2003 and MERS in 2014. Gambotto, the study of these two viruses, a protein called spike protein important to trigger immunity He said that.
New coronavirus vaccine called PittCoVacc a finger-sized patch Applied with. The researchers explained that in developing the vaccine, they have taken a more radical approach based on viral protein fragments, unlike other vaccine studies based on mRNA.
Scientists used an approach they called the micro-needle array to increase the strength of the vaccine. This micro needle array enables the delivery of spike protein pieces to the skin Consisting of 400 small needles it is a finger-sized patch. Needles made entirely of sugar and protein dissolve after some time after the vaccine is applied to the skin.
The new coronavirus vaccine, which works with the system called micro needle array, is also at high rates It can be scaled. The layers that make up the pieces of protein used in the vaccine can be duplicated when the efficiency of the vaccine is desired to be increased.
Developed by scientists from the University of Pittsburgh School of Medicine to maintain the vaccine room temperature is sufficient. The vaccine remains intact at room temperature, making it easy to transport and store the vaccine after production.
The new coronavirus vaccine called PittCoVac In tests performed on miceAntibodies against the SARS-CoV-2 virus were observed two weeks after administration of the vaccine. However, the animals have not been followed for a long time yet. Researchers say that animals are being followed up for a year in SARS and MERS vaccine studies.
The rapid spread of the coronavirus pandemic in the world causes the development processes of the vaccine to progress faster. For this reason, researchers from the University of Pittsburgh School of Medicine will also be on people they are waiting for permission to perform their first clinical tests.